BIOLOGICAL DRUGS will be at least 50% of new drug approvals in coming years. Small molecule drugs are having a tough time keeping up with this tsunami of very effective monoclonals. Those Pharma groups that have been slow to enter this brave new age of biologicals can only catch up by acquisition. And that will be costly.
http://lnkd.in/q5xemV
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022